AddLife AB (FRA:1AD1)

Q1 2026 AddLife AB Earnings Call Transcript

Apr 28, 2026 / 07:00 AM GMT

Release Date Price: €13.97 (-4.12%)

Transcript

Key Points

Positve

AddLife AB (STU:1AD1) maintained a high EBITDA margin of 12.5%, with Labtech achieving a 13.1% margin.
The company reported a 3% organic growth at the Group level, excluding the divested endoscopy business.
AddLife AB (STU:1AD1) successfully completed two acquisitions: BioSpectrum in the UK and Covachrom in Austria, enhancing their portfolio.
Advanced products in both Labtech and Medtech are driving growth and higher margins, with significant potential in genomics and gene sequencing.
The company has a strong balance sheet, supporting both organic and acquired growth, with net debt to EBITDA at 2.3, below the target of 3.

Negative

Currency fluctuations had a negative impact of 4% on growth, affecting overall financial performance.
The divestment of the endoscopy business in the UK resulted in a negative impact of 3% on growth.
Operating cash flow was seasonally weak, with a significant negative impact from working capital changes.
The Medtech segment experienced a slight decline in EBITDA margin from 13.5% to 12.8%, indicating pressure on profitability.
Doctor strikes in Spain temporarily reduced growth in the Medtech segment, affecting overall performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ALIFb.ST - AddLife AB
Q1 2026 AddLife AB Earnings Call
Apr 28, 2026 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, everyone, and a warm welcome to the AdLife first quarter presentation. As usual, we will be going through the developments in the different parts of the business as well as the financials, and after that, open up for questions. After the Q&A session, we have prepared a video from one of our subsidiaries. This time around, Bonsai Lab. So we do encourage you to stay on to listen to that very interesting video. So let's move on to the highlights of the quarter. So in the first quarter, we're pleased to note that the high margins continue, and at the same time, we are increasing the acquisition activity.

The EBITDA margin remained high at 12.5%, only slightly below the very high levels of Q1 in 2025. In Labtech, which had a really

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.